
Sign up to save your podcasts
Or


Moderator: James P. Rathmell, M.D. Participants: Rebecca L. Wu, M.D. and Max B. Kelz, M.D., Ph.D. Articles Discussed: TAK-925 (danavorexton), an Orexin Receptor 2 Agonist, Reduces Opioid-Induced Respiratory Depression and Sedation Without Affecting Analgesia in Healthy Adult Males Alluring Potential to Accelerate Emergence and Ameliorate Opioid-induced Respiratory Depression without Antagonizing Analgesia: Danavorexton Enters the Anesthetic Landscape Transcript
By Anesthesiology, the journal of the American Society of Anesthesiologists4.2
4444 ratings
Moderator: James P. Rathmell, M.D. Participants: Rebecca L. Wu, M.D. and Max B. Kelz, M.D., Ph.D. Articles Discussed: TAK-925 (danavorexton), an Orexin Receptor 2 Agonist, Reduces Opioid-Induced Respiratory Depression and Sedation Without Affecting Analgesia in Healthy Adult Males Alluring Potential to Accelerate Emergence and Ameliorate Opioid-induced Respiratory Depression without Antagonizing Analgesia: Danavorexton Enters the Anesthetic Landscape Transcript

1,877 Listeners

134 Listeners

321 Listeners

504 Listeners

1,468 Listeners

2,455 Listeners

1,150 Listeners

281 Listeners

260 Listeners

437 Listeners

227 Listeners

20 Listeners

375 Listeners

25 Listeners

270 Listeners